Search results
Novel Gene-Editing Therapy Continues to Show Posit | Newswise
Newswise· 23 hours agoConducted as part of the multicenter RUBY Trial, researchers shared data on the safety and effectiveness of renizgamglogene autogedtemcel (reni-cel, formerly known as EDIT-301), an experimental ...
New hope for those living with Sickle Cell Disorder thanks to experimental gene treatment
WSB-TV 2 Atlanta· 7 days agoThe treatment is a gene cell therapy recently approved by the U.S. Food and Drug Administration. For...
Woman Thought Baby's Facial Feature Was Trait from Dad, Then Realizes It's Symptom of Childhood...
People via Yahoo News· 1 day agoFollowing a series of tests and a "week of nerves," Lydia...New Orleans-based genetics specialist,...
These 3 Clinical-Stage Biotech Stocks Can Offer Exponential Gains | Investing.com
Investing.com· 9 hours agoStocks Analysis by The Tokenist (Timothy Fries) covering: Pfizer Inc, Ocuphire Pharma Inc, Rocket...
Health Minister JP Nadda urged to bring 'thalassemia' into national spotlight
Investing.com· 23 hours agoHealth Minister JP Nadda urged to bring 'thalassemia' into national spotlight
Risk of secondary cancers after CAR-T cell therapy low, according to large study
Medical Xpress· 2 days agoA large study by researchers at Stanford Medicine has found that the risk of secondary blood cancers...
Study Elucidates Skin Signs of VEXAS Syndrome
Medscape· 23 hours agoSkin manifestations are common in the vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome and present early in the disease course....
Sernova Provides Update on Public Offering
NewMediaWire via Yahoo Finance· 2 days agoLONDON, Ontario and BOSTON, Massachusetts - (NewMediaWire) - June 12, 2024 - Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage...
2 Healthcare Stocks to Buy Hand Over Fist in June
The Motley Fool via AOL· 3 days agoCF is a rare genetic disorder that causes damage to various internal organs. Vertex's leadership...innovating, as evidenced by positive phase 3 data for...
Takeda circles a leukemia drug; J.P. Morgan moves into biotech investing
BioPharma Dive via Yahoo Finance· 17 hours agoThe Japanese pharma paid $100 million to secure option rights to an Ascentage drug. Elsewhere, J.P....